Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.15
-0.06 (-0.83%)
Apr 8, 2026, 11:18 AM EDT - Market open
Karyopharm Therapeutics Revenue
In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth. Karyopharm Therapeutics had revenue of $34.08M in the quarter ending December 31, 2025, with 11.58% growth.
Revenue (ttm)
$146.07M
Revenue Growth
+0.57%
P/S Ratio
1.11
Revenue / Employee
$640,645
Employees
228
Market Cap
161.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Black Diamond Therapeutics | 70.00M |
| Spero Therapeutics | 66.80M |
| Sangamo Therapeutics | 39.55M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Fate Therapeutics | 6.65M |
| Equillium | 4.39M |
KPTI News
- 14 days ago - Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Benzinga
- 15 days ago - Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - Reuters
- 15 days ago - Karyopharm Announces $30 Million Private Placement with RA Capital - PRNewsWire
- 15 days ago - Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - PRNewsWire
- 5 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 2 months ago - Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - PRNewsWire
- 3 months ago - Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - PRNewsWire